Partial Parallelism Plots
Source abstract
Abstract
Demonstrating parallelism in quantitative laboratory tests is crucial to ensure accurate reporting of data and minimise risks to patients. Regulatory authorities make the demonstration of parallelism before clinical use approval mandate. However, achieving statistical parallelism can be arduous, especially when parallelism is limited to a subrange of the data. To address potential biases and confounds, I propose a simple graphical method, the Partial Parallelism Plot, to demonstrate partial parallelism. The proposed method offers ease of understanding, intuitiveness, and graphical simplicity. It enables the graphical assessment of quantitative data risk when parallelism is lacking within a defined range. As parallelism may not be consistent across the entire analytical range, the plots focus on partial parallelism. The method can readily be programmed into graphical applications for enhanced interactivity. By providing a clear graphical representation, the method allows researchers to ascertain the presence of parallelism in laboratory tests, thus aiding in the validation process for trials and clinical applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Statistical Methods in Clinical Trials · Cell Image Analysis Techniques · Metabolomics and Mass Spectrometry Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Queen Square Institute of Neurology, UCL, London WC1N 3BG, UK
Amsterdam UMC, De Boelelaan 1117, 11081 HX Amsterdam, The Netherlands
References (17)
Show source-provided references
1. Determination of parallelism and nonparallelism in bioassay dilution curves10.1128/jcm.32.10.2441-2447.1994 ↗
2. Pum, J. (2019). Advances in Clinical Chemistry, Elsevier.
3. 2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (Part 2—Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation)10.4155/bio-2022-0080 ↗
4. (2023, July 27). ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf.
5. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament hook effect10.1016/j.jneumeth.2010.11.026 ↗
6. Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review10.3389/fnagi.2022.683689 ↗
7. Ofatumumab versus Teriflunomide in Multiple Sclerosis10.1056/NEJMoa1917246 ↗
8. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS10.1056/NEJMoa2204705 ↗
9. Burtis, C., and Ashwood, E. (1994). Tietz Textbook of Clinical Chemistry, WB Saunders. [2nd ed.].
10. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking10.1212/WNL.0b013e3181c47cc2 ↗
11. Neurofilament ELISA validation10.1016/j.jim.2009.09.014 ↗
12. Grötsch, M.K., Wietor, D.M., Hettich, T., and Ehlert, U. (2022). Validation of a Commercial Enzyme-Linked Immunosorbent Assay for Allopregnanolone in the Saliva of Healthy Pregnant Women. Biomolecules, 12.10.3390/biom12101381 ↗
13. A Modified Ultra-Sensitive ELISA for Measurement of LH in Mice10.1210/endocr/bqac109 ↗
14. Diepeveen, L., Roelofs, R., Grebenchtchikov, N., van Swelm, R., Kautz, L., and Swinkels, D. (2021). Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone. PLoS ONE, 16.10.1371/journal.pone.0254851 ↗
15. Development of a novel ELISA for human insulin using monoclonal antibodies produced in serum-free cell culture medium10.1016/j.clinbiochem.2006.10.004 ↗
16. Critical difference calculations revised: Inclusion of variation in standard deviation with analyte concentration10.1258/acb.2009.009083 ↗
17. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: Pros and cons10.4155/bio-2017-0084 ↗